• Save lifetimes

    Save lifetimes

    Today’s time-consuming diagnosis of sepsis leads to prolonged patient hospitalization, increased mortality, and an overuse of broad-spectrum antibiotics. Q-linea’s fully automated ASTar® system cuts the diagnostic time by half and delivers clinically-actionable results – when time is life

    Learn more >

    Today’s time-consuming diagnosis of sepsis leads to prolonged patient hospitalization, increased mortality, and an overuse of broad-spectrum antibiotics. Q-linea’s fully automated ASTar® system cuts the diagnostic time by half and delivers clinically-actionable results – when time is life

    Learn more >

  • Q-linea as an investment

    Q-linea as an investment

    Q-linea is an innovative infection diagnostics company whose ambition is to offer products that benefit patients, healthcare providers and society

    Learn more >

    Q-linea is an innovative infection diagnostics company whose ambition is to offer products that benefit patients, healthcare providers and society

    Learn more >

News & events

Press releases

2020/10/29

Invitation to presentation of Q-linea’s Interim report Q3-2020 on November 5, 2020

Press releases

2020/10/28

Webinar Tuesday November 10th: Equal and better care for everyone

Press releases

2020/09/04

Q-linea installs the first ASTar system at Uppsala University Hospital

All news & events >
User testimonial;
How ASTar has helped
save time in the lab

Listen to Ehsan Ghaderi, Head of Dept, and Sofia Persson, Consultant Physician, Bacteriology, Uppsala University Hospital, Sweden

Watch video >
 You can minimise a lot of side effects related to broad-spectrum treatment by being able to target the antimicrobial treatment at a very early stage

Professor Christian Giske, Karolinska Institute, Sweden

Read more >
User testimonial;
How ASTar has helped
save time in the lab

Listen to Ehsan Ghaderi, Head of Dept, and Sofia Persson, Consultant Physician, Bacteriology, Uppsala University Hospital, Sweden

Watch video >
 You can minimise a lot of side effects related to broad-spectrum treatment by being able to target the antimicrobial treatment at a very early stage

Professor Christian Giske, Karolinska Institute, Sweden

Read more >